{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-25-000010","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.450251+00:00","generated_at":"2026-05-26T22:46:13.653523+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AnaptysBio reports Phase 2b RA trial success; rosnilimab hits primary endpoint, 69% CDAI LDA at week 14","bullets":["Phase 2b RENOIR trial (n=424) met primary endpoint (mean DAS-28 CRP change at week 12) across all three doses vs placebo (p<0.01).","At week 14, 69% of rosnilimab-treated patients achieved CDAI low disease activity, described as highest ever reported.","Favorable safety: no malignancies, no MACE, no serious infection elevation vs placebo; discontinuations low at 1-2%.","Full week 28 data expected Q2 2025; top-line week 12 rosnilimab UC data now anticipated in Q4 2025.","CEO states results exceed target product profile in ~$20B U.S. RA market."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-25-000010","json":"https://secwatch.observer/filing/0001370053-25-000010.json","markdown":"https://secwatch.observer/filing/0001370053-25-000010.md","text":"https://secwatch.observer/filing/0001370053-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000010/0001370053-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000010/anab-20250212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:46:13.653523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}